hormone replacement therapy news from FiercePharma
News
New drug-spending leader: Diabetes
New data on pharma sales details some big shifts in spending. Diabetes meds have displaced cholesterol drugs as the Read more...
ALSO NOTED: Genzyme can't make Myozyme at Boston plant; Ranbaxy, Orchid forge drug-and-API deal;
> FDA won't let Genzyme make its uber-expensive Pompe disease treatment Myozyme at its Boston plant because of a small difference between the batches of Myozyme Genzyme makes now and the new Read more...
ALSO NOTED: Appeals court votes for FDA approval shield; Suicides rose as depression treatment fell;
> A federal appeals court backed the drug industry's arguments that it should be insulated from lawsuits over FDA-approved products, ruling 2-1 that antidepressant makers GlaxoSmithKline and Read more...
Cancer risk lingers when hormones stop
Remember all the brouhaha over the Women's Health Initiative study, which showed that women using hormone therapy were more likely to develop breast cancer and also had increased risk of Read more...
Get more hormone replacement therapy coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends